Skip to content
DeeptechNavigator

Insights · tech brief

AI Imaging Diagnostics in India: Tackling Brain, Lung, and Data Challenges

From brain tumor detection to COVID-19 lung scans, Indian innovators are building AI tools that overcome data scarcity and resource constraints to speed up accurate diagnoses.

Published 21 Jul 2026

Market Momentum
rising
AI Adoption in Imaging
accelerating
India MedTech Growth
double-digit trajectory

The problems being solved

Manual analysis of MRI and CT scans remains slow, subjective, and error-prone, delaying treatment for brain tumors. Radiologists must distinguish tumor types and boundaries, a task where fatigue and variability creep in. Innovators are targeting automated detection and classification that also surfaces interpretable reasoning, so clinicians can trust the output.

During the pandemic, overburdened diagnostic centers and slow RT-PCR results created an urgent need for fast, automated COVID-19 detection from chest X-rays and CT scans. The challenge was compounded by imbalanced datasets and the risk of false alarms, pushing work toward ensemble models that combine multiple imaging modalities.

Lung diseases—pneumonia, lung cancer, nodules—suffer from similar bottlenecks. Diagnosis often requires expert radiologists who are in short supply, especially outside major cities. Automated tools must work on edge devices with limited compute, integrate with electronic medical records, and preserve patient privacy when training across hospitals.

Underlying all this is a data problem: heterogeneous, non-IID datasets scattered across institutions, strict privacy requirements, and the need to train robust models without pooling sensitive images. Resource-constrained settings demand lightweight models that can run on portable or point-of-care devices.

How the field is solving it

Deep convolutional neural networks form the backbone, with architectures like DarkNet, YOLO, ResNet, and Inception-ResNet-v2 being adapted for specific diseases. Transfer learning from pre-trained models such as VGG16, ResNet50, and EfficientNetV2L helps overcome limited local datasets.

Ensemble and hybrid techniques are reducing false alarms by combining multiple classifiers—for instance, fusing CNN features with Random Committee or fuzzy logic with PCA. This is especially visible in COVID-19 detection, where stacking models trained on both CT and X-ray images lifts accuracy.

Privacy-preserving collaboration is emerging through federated learning, often paired with blockchain for audit trails. This allows hospitals to jointly train lung cancer or pneumonia detectors without moving patient data. Edge-optimized models are being designed to run inference directly on low-power devices, crucial for rural screening.

Vision Transformers are beginning to appear alongside traditional computer vision pipelines, tackling thoracic abnormality detection and multi-modal data fusion. Some systems integrate diagnostic output with provider selection and feedback loops, moving beyond pure classification toward clinical decision support.

Where the market is heading

Globally, the diagnostic imaging market sits at roughly USD 26–27 billion and is projected to reach over USD 32 billion by 2030, growing at a low-single-digit annual rate (MarketsandMarkets). The broader medical imaging equipment market is larger—around USD 44 billion in 2025, expected to climb to nearly USD 79 billion by 2034 (Fortune Business Insights). Asia Pacific already accounts for close to 40% of that market.

India’s MedTech sector, valued at USD 16–20 billion, is on a double-digit growth trajectory toward USD 24–30 billion by 2030 (PhotonDelta). The Ayushman Bharat Digital Mission is building a national digital health backbone, creating large-scale testbeds for AI-driven imaging and integration with electronic health records.

Several trends are shaping demand: AI and computer-aided diagnostics are becoming standard in TB screening programs (PFSCM); portable and mobile MRI solutions are expanding access to underserved areas; and supply chain disruptions are pushing hospitals to rethink capital equipment dependencies. Imaging’s role in infectious disease management, highlighted by COVID-19, is now extending to tuberculosis and other respiratory illnesses.

Price sensitivity remains a defining feature of the Indian market. Solutions that deliver high accuracy on affordable hardware, or that retrofit existing X-ray machines with AI, are likely to see faster adoption.

The white space

Federated learning on non-IID data is still maturing—there is room for frameworks that handle the extreme heterogeneity of Indian hospital datasets without sacrificing model performance. Pairing this with lightweight, explainable models for edge deployment opens a path to truly rural-first diagnostic AI.

Multi-modal integration remains underexplored. Combining imaging with pathology, genomics, or electronic health records could dramatically improve diagnostic precision, yet few systems attempt this in a privacy-compliant manner. Interpretability is another gap: clinicians need more than a black-box prediction; they need visual explanations and confidence scores they can act on.

Portable imaging hardware, such as mobile MRI or handheld ultrasound, is gaining traction globally. Indian innovators can couple these devices with AI that runs offline, syncing later with central registries. The ABDM infrastructure offers a ready-made platform for such connected diagnostics, but the tools to plug into it are still being built.

Beyond COVID-19, automated screening for tuberculosis, chronic obstructive pulmonary disease, and lung cancer represents a large, underserved need. Solutions that work with the low-dose CT scans and chest X-rays already available in district hospitals could have immediate public health impact.

Explore the innovators

The specific inventors, patents, and companies working on these challenges in India can be explored on Deeptech Navigator. Dive into the details of brain tumor segmentation models, federated learning frameworks for lung cancer, and edge AI for pneumonia detection—all emerging from India’s deep-tech ecosystem. The platform reveals who is building what, and where the novel technical approaches are being protected.

Knowledge graph

How the technologies, companies and players in this briefing connect.

problem

Brain Tumor DetectionCOVID-19 DiagnosisPulmonary Disease DetectionData PrivacyResource Constraints

approach

Convolutional Neural NetworksEnsemble & Hybrid MethodsTransfer LearningFederated LearningEdge AIVision Transformers

technology

MRICTX-rayPortable Imaging

application

ABDM Integration

In our data

Sources

This briefing is AI-generated from Deeptech Navigator's patent and startup data and lightly reviewed before publishing. Treat it as a starting point, not professional advice - figures are directional, so verify before relying on any number. The platform takes no responsibility for decisions made on it.

Related briefings

funding brief

The RDI Fund's 19 New Managers Get ₹7,131 Crore. The Companies They Back Raised ₹2,823 Crore Last Year.

India's RDI Fund has approved its first 19 private and research-body fund managers. In our data they are linked to 276 deep-tech companies, 1% of our list, which closed ₹2,823 crore of named private equity rounds in the past year. The commitment equals 33% of a year of such rounds across all deep-tech companies on our list.

funding brief

Space Took a Quarter of the RDI Fund's First Approvals. AI Took ₹3 Crore.

We set TDB's first 22 RDI approvals against where India's deep-tech companies and patent filings are. Space took a quarter of the money from 2% of the companies on our list. AI took 0.1%. Karnataka sent nearly a third of the proposals; Gujarat sent four.

funding brief

Missions Outspend Investors 115 to 1 in Chips. In Space, Investors Lead 7 to 1.

We set ten government missions and funds against the private rounds on our record in the same sectors. In chips, quantum, critical minerals and green hydrogen, the state has committed more than every private round the sector's startups have on our record. In space, robotics, defence, health and mobility, investors have put in more. AI is close to level.

funding brief

The RDI Fund Pays Half. How Many Indian Deeptech Companies Can Raise the Other Half?

The ₹1 lakh crore RDI Fund will finance no more than half of a project; the company must find the rest. The first 22 approvals needed a median ₹101 crore each from their own or private sources. In the past year, 47 deep-tech companies on our list closed a private round of ₹100 crore or more.

funding brief

The RDI Fund's First 22 Companies: ₹2,192 Crore Approved, ₹376 Crore Paid

The Technology Development Board, the first manager to lend from India's ₹1 lakh crore Research, Development and Innovation Fund, has approved 22 companies for ₹2,192 crore against projects worth ₹4,744 crore. By 30 September it had paid ten of them ₹375.69 crore. Here is the full list, what each is building, and what our data says about them.

tech brief

Indian Deeptech Reaches Series B at 7%. Its Space Companies Do It at 19%.

A reader asked whether our Series B figure was a real graduation rate. It was not, so we recomputed it. The deeptech-versus-everything-else gap did not survive the recount. The gap inside deeptech did, and it runs from zero to nineteen percent.

Get in touch

Have a question on this - or want it researched for you?

Send a note: feedback on this briefing, a data question, or a scoped custom study on your specific market, geography or patent question. No account or card needed - we reply by email, usually within 1 business day.

No card charged, no account needed - we reply by email.